Similar articles

Abstract: Radiation therapy has been widely applied in cancer treatment. However, it often causes thrombocytopenia (deficiency of white blood cells) as an adverse effect. recombinant human interleukin-6 (rhIL-6) has been found to be a very effective way against this thrombocytopenia, but IL-6 has low stability in blood, which reduces its efficacy. To increases the stability and half-life of rhIL-6, it was modified by polyethylene glycol (PEG). The pharmacokinetics and the tissue distribution of PEG-rhIL-6 labeled with ¹²⁵I were examined after subcutaneous injection in rats. The pharmacokinetic pattern of PEG-rhIL-6 was defined with linear-kinetics, and we fitted a one-compartment model with half-lives of 10.44–11.37 h (absorption, t_1/2Ka) and 19.77–21.53 h (elimination, t_1/2Ke), and peak concentrations at 20.51–21.96 h (t_peak) in rats. Half-lives and t_peak of PEG-rhIL-6 were longer than those of rhIL-6 previously reported. In the present study, for deposition of PEG-rhIL-6 in rats, the tissue distribution examination showed that blood was the major organ involved, rather than liver. However, as to the elimination of PEG-rhIL-6, the major organ was the kidney. The excretion fraction of the injection dose recovered from urine was 23.32% at 192 h after subcutaneous administration. Less than 6% of PEG-rhIL-6 was eliminated via the feces at 192 h. These results indicate that PEG-rhIL-6 is a good candidate drug formulation for patients with cancer.

[1]Bailon, P., Palleroni, A., Schaffer, C.A., Spence, C.L., Fung, W.J., Porter, J.E., Ehrlich, G.K., Pan, W., Xu, Z.X., Modi, M.W., et al., 2001. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem., 12(2):195-202.

[2]Banks, R.E., Forbes, M.A., Patel, P.M., Storr, M., Hallam, S., Clarke, D., Novick, D., Ingham, E., Bowmer, C., Southgate, J., et al., 2000. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Cytokine, 12(4):388-396.

[3]Bracho, F., Krailo, M.D., Shen, V., Bergeron, S., Davenport, V., Liu-Mares, W., Blazar, B.R., Panoskaltsis-Mortari, A., van de Ven, C., Secola, R., et al., 2001. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/ refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin. Cancer Res., 7(1):58-67.

[4]Caliceti, P., Veronese, F.M., 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev., 55(10):1261-1277.

[5]Castell, J.V., Geiger, T., Gross, V., Andus, T., Walter, E., Hirano, T., Kishimoto, T., Heinrich, P.C., 1988. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Biochem., 177(2):357-361.

[6]Castell, J.V., Klapprot, J., Gross, V., Walter, E., Andus, T., Snyers, L., Content, J., Heinrich, P.C., 1990. Fate of interleukin-6 in the rat. Eur. J. Biochem., 189(1):113-118.

[7]Cindric, M., Cepo, T., Galic, N., Bukvic-Krajacic, M., Tomczyk, N., Vissers, J.P., Bindila, L., Peter-Katalinic, J., 2007. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J. Pharm. Biomed. Anal., 44(2):388-395.

[8]Dosio, F., Arpicco, S., Brusa, P., Stella, B., Cattel, L., 2001. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. J. Control Release, 76(1-2):107-117.

[9]Drayer, A.L., Sibinga, C.T., Blom, N.R., de Wolf, J.T., Vellenga, E., 2000. The in vitro effects of cytokines on expansion and migration of megakaryocyte progenitors. Br. J. Haematol., 109(4):776-784.

[10]Hinds, K.D., Kim, S.W., 2002. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev., 54(4):505-530.

[11]Hu, Z.P., Niu, H.S., Yang, X.X., Li, H.F., Sang, G.W., Li, B., 2006. Recombinant human parathyroid hormone 1–34: pharmacokinetics, tissue distribution and excretion in rats. Int. J. Pharm., 317:144-154.

[12]Kashiwakura, I., Inanami, O., Abe, Y., Takahashi, T.A., Kuwabara, M., 2005. Different radiosensitive megakaryocytic progenitor cells exist in steady-state human peripheral blood. Radiat. Res., 164(1):10-16.

[13]Kishimoto, T., 2003. Interleukin-6 (IL-6). In: Thomson, A.W., Lotze, M.T. (Eds.), The Cytokine Handbook, 4th Ed. Vol. 1, Academic Press, New York, p.281-304.

[14]Kishimoto, T., 2005. Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol., 23(1):1-21.

[15]Kishimoto, T., 2010. IL-6: from its discovery to clinical applications. Int. Immunol., 22(5):347-352.

[16]Kodera, Y., Tanaka, H., Matsushima, A., Inada, Y., 1992. Chemical modification of l-asparaginase with a comb-shaped copolymer of polyethylene glycol derivative and maleic anhydride. Biochem. Biophys. Res. Commun., 184(1):144-148.

[17]Kozlowski, A., Charles, S.A., Harris, J.M., 2001. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs, 15(7):419-429.

[18]Levy, Y., Hershfield, M.S., Fernandez-Mejia, C., Polmar, S.H., Scudiery, D., Berger, M., Sorensen, R.U., 1988. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J. Pediatr., 113(2):312-317.

[19]Markwell, M.A., 1982. A new solid-state reagent to iodinate proteins. Anal. Biochem., 125(2):427-432.

[20]Mehvar, R., 2000. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. Pharm. Pharmaceut. Sci., 3(1):125-136.

[21]Nakanishi, H., Yoshioka, K., Joyama, S., Araki, N., Myoui, A., Ishiguro, S., Ueda, T., Yoshikawa, H., Itoh, K., 2004. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line. Am. J. Pathol., 165(2):471-480.

[22]Nojima, Y., Suzuki, Y., Iguchi, K., Shiga, T., Iwata, A., Fujimoto, T., Yoshida, K., Shimizu, H., Takeuchi, T., Sato, A., 2008. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration. Bioconjug. Chem., 19(11):2253-2259.

[23]Parveen, S., Sahoo, S.K., 2006. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin. Pharmacokinet., 45(10):965-988.

[24]Pradhananga, S., Wilkinson, I., Ross, R.J., 2002. Pegvisomant: structure and function. J. Mol. Endocrinol., 29(1):11-14.

[25]Rawat, S., Suri, C.R., Sahoo, D.K., 2010. Molecular mechanism of polyethylene glycol mediated stabilization of protein. Biochem. Biophys. Res. Commun., 392(4):561-566.

[26]Ryffel, B., Car, B.D., Woerly, G., Weber, M., DiPadova, F., Kammuller, M., Klug, S., Neubert, R., Neubert, D., 1994. Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate—the marmoset. Blood, 83(8):2093-2102.

[27]Shibata, H., Nakagawa, S., Tsutsumi, Y., 2005. Optimization of protein therapies by polymer-conjugation as an effective DDS. Molecules, 10(1):162-180.

[28]Tsunoda, S., Ishikawa, T., Watanabe, M., Kamada, H., Yamamoto, Y., Tsutsumi, Y., Hirano, T., Mayumi, T., 2001. Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent. Br. J. Haematol., 112(1):181-188.

[29]Wang, Y.S., Youngster, S., Grace, M., Bausch, J., Bordens, R., Wyss, D.F., 2002. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev., 54(4):547-570.

[30]Yin, H.L., He, X.L., Xu, B., Liu, X., Yang, G., 2005. The impedance effects of the interleukin-6 on hematopoietic damnification of cyclophosphamide-induced dogs. J. Biomed. Eng., 22(4):798-801 (in Chinese).

[31]Zeuzem, S., Welsch, C., Herrmann, E., 2003. Pharmacokinetics of peginterferons. Semin. Liver Dis., 23(Supp1. 1):23-28.

[32]Zha, J.Q., Zheng, Q.X., Li, Y.L., 1995. Pharmacokinetics of interleukin-6 in mouse. Guangdong Pharm., 5(3):53-54 (in Chinese).

[33]Zhang, Y.J., Xu, Y.J., Zhu, R., Hu, M.J., Li, J.X., Chen, Y.J., Wang, D.J., Fan, W., 2007. Pharmacokinetics, tissue distribution and excretion of a recombinant fusion protein ¹²⁵I-rhTNT-IL2. J. Radioanalyt. Nucl. Chem., 273(1):3-8.